Iodine-131-labeled meta-iodobenzylguanidine therapy of children with neuroblastoma: program planning and initial experience.

@article{Shusterman2011Iodine131labeledMT,
  title={Iodine-131-labeled meta-iodobenzylguanidine therapy of children with neuroblastoma: program planning and initial experience.},
  author={Suzanne Shusterman and Frederick D. Grant and William A Lorenzen and Royal T. Davis and Stephen Laffin and Laura A. Drubach and Frederic H. Fahey and Sandra Treves},
  journal={Seminars in nuclear medicine},
  year={2011},
  volume={41 5},
  pages={354-63}
}
Patients with high-risk neuroblastoma have a poor prognosis, especially in cases of recurrent or relapsed disease. Iodine-131-labeled meta-iodobenzylguanidine ((131)I-MIBG) can be an effective and relatively well-tolerated agent for the treatment of refractory neuroblastoma. Establishing an MIBG therapy program requires a great deal of planning… CONTINUE READING